Apollomics receives a Nasdaq deficiency notice regarding the minimum market value requirement. It terminates the Launxp deal and regains rights to vebreltinib (APL-101) in Asia outside Mainland China and Macau.
Jun 2026 · Apollomics IR / GlobeNewswireNews article
Apollomics reports its full-year 2025 financial results and business progress, including reduced expenses and its cash position. The company also provides clinical updates on the ongoing Phase 2 SPARTA trial of vebreltinib.
Apr 2026 · Apollomics IR / GlobeNewswireNews article
Apollomics Inc. announces a $2.0 million bridge financing in April 2026. The company says the financing supports ongoing operations and pipeline advancement.
Qiming Venture Partners welcomes Apollomics’ Nasdaq listing through a business combination in March 2023. Qiming says it was one of Apollomics’ earliest investors, investing since the Pre-A round.
